GCM
ICPT

Graham Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Graham Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40,000
Closed -$2.34M – 143
2017
Q4 		$2.34M Buy
+40,000
New +$2.52M 0.06% 61

Other funds holding ICPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Graham Capital Management's ICPT Position: Q3 2023 in Review

Graham Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 15,376 shares — an estimated $170K sold.

Graham Capital Management first reported a position in ICPT in Q3 2022 and held it in 2 quarters. The position peaked at $1.68M in Q3 2022. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • Graham Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Graham Capital Management sold 15,376 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $170K.
  • Graham Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
  • Graham Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.68M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Graham Capital Management's 13F filing for Q3 2023, filed 22 Nov 2023.